Publications dans lesquelles il/elle collabore avec Félix Gutiérrez Rodero (22)

2019

  1. Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain

    Open Forum Infectious Diseases, Vol. 6, Núm. 2

  2. HTLV testing of solid organ transplant donors

    Clinical Transplantation

  3. HTLV-1 infection in solid organ transplant donors and recipients in Spain

    BMC Infectious Diseases, Vol. 19, Núm. 1

2017

  1. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088

  2. HIV type 2 epidemic in Spain: Challenges and missing opportunities

    AIDS, Vol. 31, Núm. 10, pp. 1353-1364

  3. Human T-lymphotropic virus type 1 infection and disease in Spain

    AIDS, Vol. 31, Núm. 12, pp. 1653-1663

2015

  1. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  2. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. HIV-2 and HTLV-1 infections in Spain, a non-endemic region

    AIDS Reviews, Vol. 16, Núm. 3, pp. 152-159

  2. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 8, pp. 2191-2194

  3. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

  4. X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain

    AIDS, Vol. 28, Núm. 11, pp. 1603-1609

2013

  1. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens

    Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 6, pp. 2873-2878

  2. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

  3. Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations

    AIDS Research and Human Retroviruses, Vol. 28, Núm. 2, pp. 156-164

2011

  1. A highly sensitive and specific model for predicting HIV-1 tropism in treatment-experienced patients combining interpretation of V3 loop sequences and clinical parameters

    Journal of Acquired Immune Deficiency Syndromes, Vol. 56, Núm. 1, pp. 51-58

  2. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients - Impact of HIV subtypes and prior raltegravir experience

    Antiviral Research, Vol. 90, Núm. 3, pp. 164-167

2010

  1. Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy

    Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 7, pp. 3018-3020

  2. Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database

    AIDS, Vol. 24, Núm. 3, pp. 469-471